Insider · CIK 0001779308

Yale Catriona

Reports to the SEC for 1 company · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001779308

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-12-09	Akero Therapeutics, Inc.D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−27.2K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−47.6K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−3,421 sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−5,032 sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−2,328 sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−70.3K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−131K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−84.1K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−33.4K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−74.1K sh	—	—	0
2025-12-09	Akero Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Development Officer	DDisposition to Issuer	−52.8K sh	—	—	0
2025-11-04	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+3,527 sh	$28.35	+$100K	70,061
2025-11-04	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+4,739 sh	$21.10	+$100K	74,800
2025-11-04	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−3,527 sh	—	—	0
2025-11-04	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−4,739 sh	—	—	0
2025-09-11	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−659 sh	$43.02	−$28.4K	90,829
2025-07-16	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+10K sh	$19.87	+$199K	101,488
2025-07-16	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−8,658 sh	$52.87	−$458K	92,830
2025-07-16	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−1,342 sh	$53.47	−$71.8K	91,488
2025-07-16	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−10K sh	—	—	131,205
2025-06-30	Akero Therapeutics, Inc.A Award	Chief Development Officer	AAward	+890 sh	$23.87	+$21.2K	91,488
2025-06-18	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−1,633 sh	$54.84	−$89.6K	90,598
2025-06-16	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+10K sh	$21.10	+$211K	102,231
2025-06-16	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−6,210 sh	$53.78	−$334K	96,021
2025-06-16	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−2,895 sh	$54.80	−$159K	93,126
2025-06-16	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−895 sh	$55.52	−$49.7K	92,231
2025-06-16	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−10K sh	—	—	0
2025-06-10	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−2,803 sh	$54.00	−$151K	92,231
2025-05-15	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+10K sh	$21.10	+$211K	105,034
2025-05-15	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−2,837 sh	$38.20	−$108K	102,197
2025-05-15	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−2,779 sh	$39.46	−$110K	99,418
2025-05-15	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−4,384 sh	$39.91	−$175K	95,034
2025-05-15	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−10K sh	—	—	10,000
2025-04-15	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+9,073 sh	$21.10	+$191K	104,107
2025-04-15	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−7,873 sh	$37.80	−$298K	96,234
2025-04-15	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−1,200 sh	$38.62	−$46.3K	95,034
2025-04-15	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−9,073 sh	—	—	20,000
2025-03-17	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+10K sh	$21.10	+$211K	105,034
2025-03-17	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−8,201 sh	$44.70	−$367K	96,833
2025-03-17	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−1,799 sh	$45.05	−$81K	95,034
2025-03-17	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−10K sh	—	—	0
2025-03-12	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−614 sh	$44.88	−$27.6K	95,034
2025-02-18	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+10K sh	$21.10	+$211K	105,648
2025-02-18	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−9,100 sh	$49.79	−$453K	96,548
2025-02-18	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−900 sh	$50.63	−$45.6K	95,648
2025-02-18	Akero Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−10K sh	—	—	10,000
2025-01-27	Akero Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+49.1K sh	$21.10	+$1.04M	144,722
2025-01-27	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−25.9K sh	$55.15	−$1.43M	118,815
2025-01-27	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−14.5K sh	$55.95	−$809K	104,348
2025-01-27	Akero Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−8,700 sh	$57.01	−$496K	95,648

Recent filings

Accepted (ET)
Dec 94
Yale Catriona0001193125-25-312100
SEC(opens sec.gov)
Nov 64
Yale Catriona0001193125-25-268032
SEC(opens sec.gov)
Sep 124
Yale Catriona0000950170-25-114665
SEC(opens sec.gov)
Jul 184
Yale Catriona0000950170-25-097013
SEC(opens sec.gov)

Companies

Akero Therapeutics, Inc.Chief Development Officer

Address

601 GATEWAY BOULEVARD SUITE 350

SOUTH SAN FRANCISCO, CA, 94080